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Abstract 
 
Background: An altered ano-rectal function is reported after chemoradiotherapy and 
surgery for rectal cancer. 
 Aim of this study was to clarify the relative contribution of neoadjuvant chemoradiation 
and surgical resection on the impairment of anorectal function as evaluated by anorectal 
manometry. 
Methods Thirty-nine patients with rectal cancer, who underwent neoadjuvant 
chemoradiotherapy and laparoscopic rectal resection, were evaluated with the Pescatori 
Fecal Incontinence score, and with anorectal manometry: before neoadjuvant therapy 
(T0), after neoadjuvant therapy and before surgery (T1), 12 months after stoma closure 
(T2).  
Results  Resting and/or maximum squeeze pressure and/or volume thresholds for urgency 
were below the normal values in 12 (30%) patients at baseline.  After chemoradiotherapy 
the mean resting pressure significantly decreased (p= 0.007). Surgery determined a 
significantly decrease of the resting pressure (p=0.001), of the maximum squeeze 
pressure (p=0.001) and of the volume threshold for urgency (p=0.001). Impairment of 
continence was reported by 5, 11 and 18 patients at T0, T1 and T2, with a mean 
incontinence score of 3, 3.8 and 3.9 respectively. 
Conclusions Chemoradiotherapy is detrimental to the function of the internal anal 
sphincter. Rectal resection significantly affects both internal and external anal sphincter 
function and the maximum tolerated volume of the neo-rectum, particularly in patients with 
low rectal cancer, significantly impairing anal continence. 
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Introduction  
 
Low anterior resection (LAR) with total mesorectal excision (TME) is the surgical standard 
procedure in sphincter-preserving therapy for cancer of the medium and low rectum [1-3]. 
Neoadjuvant chemoradiotherapy (CRT) is being used in patients with T3/T4 rectal cancer, 
or with lymph node involvement, with the purpose of reducing tumor extension and 
increasing the likelihood to perform a radical resection [4]. Literature data suggest that the 
preoperative approach is associated with less long-term toxicity and better oncological 
outcome than postoperative therapy [ 5].  
Sphincter-saving operations may give rise to anterior resection syndrome (ARS)  [6] which  
includes high bowel frequency, urgency, and fecal incontinence (FI); ARS occurrence 
increases as the level of anastomosis approaches the sphincters, with the highest 
incidence reported in patients with ultralow anterior resection and colo-anal anastomosis 
[7,8]. These symptoms are a consequence of direct damage to the sphincter complex [9], 
altered function of the anal sphincters, reduced capacity and distensibility of the neo-
rectum, colonic dismotility and denervation [10,11]. Both radiotherapy and surgery may 
adversely affect ano-rectal function and contribute to the development of ARS symptoms.  
Anorectal manometry is the preferred technique to provide objective information about the 
function of continence mechanism since it can identify functional sphincter weakness, poor 
rectal compliance, and rectal sensation impairment [12]. Therefore we performed this 
study in order to evaluate the different role of neoadjuvant CRT and surgical resection in 
determining the onset of different anorectal dysfunctions. Although clinical data were also 
considered, the study focused on ano-rectal manometry alterations.  
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Methods 
 
Patients with histologically proven medium or low rectal adenocarcinoma, referring to the 
Surgical Department of the San Raffaele Scientific Institute, between April 2011 and April 
2012, were studied. Medium and low rectal cancer were defined as tumor 7 to 11 cm and 
0 to 7 cm from the anal verge respectively, as measured by rigid proctoscopy [13]. The 
patients were staged with total body computed tomography scan, and magnetic resonance 
and echo-endoscopy of the pelvis. Patients with clinical stage T3/4 or N+ underwent 
neoadjuvant CRT. Only patients who performed both CRT and surgery at our Institution 
were included in the analysis. Patients with very low lying tumor, requiring an 
intersphincteric resection and patients whose stoma was not closed were also excluded 
(Fig 1). All the patients signed an informed consent for the procedures and for the use of 
their data for the study.  
The preoperative chemotherapy scheme consisted of oxaliplatin 100 mg/mq iv plus a 
continuous infusion of 5-fluorouracil 200 mg/mq iv for fourteen days, to be repeated every 
fourteen days for a total of 3 cycles. Radiotherapy was added from the fourteenth day of 
treatment (i.e. from the second cycle) for a total of 41.4 Gy in 18 daily doses (2.3 Gy for 
each dose). Clinical target volume for RT  included tumour visible at MRI, mesorectum, 
lymph-nodes of obturator, internal iliac, common iliac chains as well as the whole anterior 
surface of sacrum, coccyx and piriformis muscle, and ischiatic fossa;  the volume was 
expanded by 0.5 cm in all directions.   
All the patients were evaluated clinically and with anorectal manometry three times during 
their clinical course: T0: before neoadjuvant therapy, T1: after neoadjuvant therapy and 
before surgery, T2: 12 months after stoma closure. 
Anorectal manometry was performed using a custom-designed, open-tip, 14-Fr diameter, 
PVC probe with seven lumens and a 4-cm latex balloon tied at the end of the probe 
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(Bioengineering Laboratories SpA, Milan, Italy). Six lumens were connected to side ports 
for pressure.  A personal computer using version 6.4 of the Lower GI Edition Polygram for 
Windows program recorded the pressure of the side ports in a digital format. The protocol 
was applied as previously reported [14]. The following parameters were investigated and 
recorded: resting pressure, squeeze pressure, rectal sensation (first sensation, desire to 
defecate, urgency or discomfort during intermittent distension), anal responses to rectal 
distension. 
At the same time the patients scored their anal continence by using the Pescatori Fecal 
Incontinence score [15].  
The patients underwent surgery 8 to 10 weeks after completion of the neoadjuvant 
treatment. Preoperatively the patients underwent mechanical bowel preparation with 2 
litres enema, and antimicrobial prophylaxis with cefazolin 2g ev plus metronidazole 500 
mg ev, 30 min before the induction of the anaesthesia. After surgery antithrombotic 
prophylaxis with Nadroparin calcium according to patient’s weight was administered 
 
Statistical analysis  
 
Paired and unpaired data were compared with Student's t-test. Chi-square test was 
applied to comparison of percentages. Differences were considered significant with p 
<0.01 (according to Bonferroni's correction). All data are given as mean±SD. 
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Results 
 
Thirty-nine patients, 26 men (66.67%), median age 65 years (range 41-79), were studied. 
Twenty-five patients had cancer of the medium and 14 of the lower rectum. The mean 
distance of the neoplasm from the anal verge was 7.02 cm (range 3-11 cm). Clinical 
staging at diagnosis was as follow: 26 patients T3N+, 4 patients T3N0, 4 T2N+ and 5 
T4N+. Demographic and clinical data of the patients are reported in Table 1. The two 
groups of patients with cancer of medium and low rectum did not differ for any of the 
evaluated parameter (Tab 2). All the patients underwent laparoscopic low anterior 
resection with total mesorectal excision. Attention was paid to preserve pelvic autonomic 
innervation. Depending on the level of the tumor, a Knight-Griffen end-to-end anastomosis 
with a circular stapler or a hand-sewn colo-anal anastomosis was performed. A transverse 
colostomy or an ileostomy was performed at surgeon’s choice. All the patients underwent 
stoma closure 1 to 8 months after surgery 
Manometric results before neoadjuvant chemoradiotherapy 
Twelve out of 39 (30%) patients had an altered anorectal function before any treatment.  
The clinical characteristic and the FI score of the patients are reported in Table 1. The 
mean values of the manometric parameters are reported in Table 2. Mean incontinence 
score in the 5 patients was 3 (range 2-4) 
Patients with medium or low rectal cancer as a group, did not differ for any of the clinical 
and manometric parameters, except for a lower volume threshold for urgency in the 
patients with medium compared with those with low rectal cancer (p= 0.01).  
Manometric results after neoadjuvant chemoradiotherapy 
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FI was reported by 11 patients with a mean score of 3.8 (range 3-5). An anorectal 
dysfunction emerged for the first time after CRT in 9 (23%) patients. In the overall group 
CRT significantly reduced the resting pressure of the anal sphincter in comparison to the 
evaluation before any treatment (p=0.007) (Tab. 3).  
The 2 groups of patients with cancer of the medium and low rectum did not differ for any of 
the manometric parameters.  
Manometric results after surgery 
All the 25 patients with medium rectal cancer had a mechanical anastomosis; among the 
14 patients with low rectal cancer 2 had a mechanical and 12 a hand sewn colo-anal 
anastomosis. Mean distance of the tumor from the anal verge was 8.1±2.9 cm in patients 
with mechanical anastomosis and 4.4 +1.5 cm in patients with hand sewn anastomosis 
(p=0.0005) respectively. 
In the 2 groups globally an anorectal dysfunction arise for the first time in 14 (35%) 
patients, in 5 (28%) and 9 (64%) patients with tumor of the medium and low rectum 
respectively. Eighteen patients globally and 7 for the first time showed FI with a mean 
score of 3.9 (range 3-5).  
Surgery significantly reduced the resting pressure, the maximum squeeze pressure and 
volume threshold for urgency in comparison with the evaluation after CRT (all p< 0.001) 
and before any treatment (all p< 0.001) (Tab. 3) these manometric alterations, as well as 
FI, occurred with a greater frequency in patients with low than medium  rectal cancer (64% 
vs 28%, p< 0.03) (Tab. 4). Moreover incontinence symptoms were present in 9out of 12 
patients (75%) with hand sewn and in 9 out of 27 (33%) with mechanical anastomosis 
(p=0.03).  
Other predictive factors for anorectal function impairment were female sex, age >60, and 
hand sewn anastomosis (Tab …).  
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Discussion 
 
Neoadjuvant chemo radiotherapy has become the standard treatment for patients with 
locally advanced rectal cancer. When compared to surgery alone, local tumor control, anal 
sphincter preservation and disease free survival improvement have been demonstrated 
[16,17]. Potential adverse effects of radiation therapy on the gastrointestinal tract, 
however, should not be neglected. After neoadjuvant therapy and surgery, patients 
frequently complain of altered continence which is associated with a corresponding 
alteration in the function of the anal sphincter and with an impaired capacity and 
distensibility of the neo-rectum [18]. Moreover irradiated patients, compared with patients 
who underwent TME alone, more likely reported fecal incontinence and less satisfaction 
with bowel function [19-21]. While pelvic irradiation may cause vascular toxicity and 
damage to the anal sphincter muscles and pudendal nerve [22], surgery may possibly lead 
to damage of the innervation of the lower gastrointestinal tract, and a reduced capacity 
and distensibility of the neo-rectum.  
Many authors underlined the adverse effects of radiotherapy on maximal squeeze 
pressure [23], on incontinence score [24], or pudendal nerve terminal motor latency [25]. 
Histological changes have been demonstrated in the irradiated internal anal sphincter with 
increase in collagen fibers and alteration of myenteric plexus [26]. Recently Lorenzi at Al 
studied “in vitro” strips of irradiated internal anal sphincter and demonstrated a reduced 
spontaneous activity compared with controls [27].  
Only few studies have addressed the role of radiotherapy as a contributing factor for the 
development of anorectal dysfunction or incontinence, and there are only limited data, and 
no randomized studies, concerning  postoperative functional outcome of rectal cancer 
patients who underwent long course neoadjuvant CRT. 
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Ammann et Al. studied with anorectal manometry 2 groups of patients whit cancer of the 
medium or low rectum, who underwent TME surgery with or without nCRT, and found that 
chemoradiation adversely affect sphincter function, being the mean resting pressure, the 
resting vector volume and the maximum tolerated volume significatively impaired 
postoperatively  in the chemoradiated patients, (28). In a similar study Canda et Al. 
observed a significant reduction in anal canal resting pressures and squeeze pressures, 
as well as Wexner Incontinence score, and Fecal Incontinence Quality of Life score  
immediately after the completion of  preoperative chemoradiotherapy (23). On the basis of 
their results the Authors suggested to better identify patients at risk to develop functional 
problems and to select the patients who will benefit from neoadjuvant therapy.  An impact 
on internal sphincter function and an higher incidence of incontinence in irradiated patients 
was also reported by Gervaz et Al. who suggested that individual characteristics may 
determine different susceptibility to radiation-induced damage (29).   
Since the majority of the studies examined patients only after surgery, it is difficult to 
evaluate to which extent the post surgical impairment is caused by CRT or surgery. Our 
study is designed to try to clarify the weight of neoadjuvant therapy in determining 
anorectal dysfunction by evaluating an homogeneous group of patients, clinically and with 
anorectal manometry, who underwent to the same chemo-radiation protocol and surgical 
procedure, not only after surgery but also before surgery and after neoadjuvant therapy.  
The present study demonstrates that at baseline, before any treatment, 8% of patients 
have a dysfunction of resting and squeeze pressure of anal sphincters and 23% have a 
lower maximum tolerated rectal volume. These dysfunctions have never been reported in 
the literature in patients with rectal cancer. Considering the range of age of the population 
of the patients in the study (median age 60), they confirm the decrease of anal resting tone 
and squeeze with advancing age [30-32]. However, since the sphincter integrity has not 
been evaluated preoperatively, unknown sphincter injuries could have also determined low 
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resting or squeezing pressure before CRT. On the contrary, no relationship has been 
demonstrated between age and rectal sensory thresholds, therefore in this setting, the 
abnormal values are probably the result of the presence of the tumor. Also the result 
concerning the presence of faecal incontinence in this population of patients has never 
been reported before but is in line with the prevalence of this dysfunction in population of 
patients in the same range of age [33]. 
After neoadjuvant treatment, another 23% of patients, showed the new onset of anorectal 
dysfunctions, mostly represented by a lower resting anal pressure. As the resting pressure 
mainly reflects the function of the internal anal sphincter, this data confirms the reported 
tropism of radiation damages for smooth muscle [34]. This finding was previously noted by 
Bakx that studied a group of patients after short term preoperative radiotherapy and found 
a significant difference in the resting pressure compared to healthy volunteers [35]. It is 
likely that radiotherapy may act as a detrimental factor causing fibrosis of internal anal 
sphincter, as found by Pollack with endoanal ultrasound [21].  In contrast, other studies 
reported either no influence of CRT on resting pressure [36] or a reduction of the squeeze 
pressure [25] or of both resting and squeeze pressure [23, 22]. These different results 
could be explained by several factors, such as the different dose and volume of irradiation 
among studies or the type of chemotherapy administered concurrently with RT. The 
National Comprehensive Cancer Network NCCN guidelines indicate either infusional FU or 
capecitabine combined with long course RT as suggested neoadjuvant treatment for 
patients with locally advanced rectal cancer [1]. Starting from 2002, in an attempt to 
reduce the risk of systemic metastases, in our Institute oxaliplatin was added to 
fluorouracil-based/RT regimens, which was reported to increase toxicity. Several studies 
addressed the addition of oxaliplatin to neoadjuvant treatment, with controversial results: 
while no improvement in pathological complete response has been found in some studies 
[37], in the recent CAO/ARO/AIO-04 trial, a significant improvement in 3 years disease-
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free survival was noted. Moreover, with a schedule similar to our protocol, a good 
compliance, acceptable toxicity, and low surgical morbidity was reported [38] 
To be noted that after chemoradiation faecal incontinence occurred also in patients without 
any anorectal dysfunction measured by anorectal manometry. This could be related to the 
altered bowel habit induced by the CRT that was not recorded in the present study.   
After low anterior resection and TME, another 35% of patients showed an anorectal 
dysfunction represented by a lower resting and/or squeeze pressure with or without a 
lower maximum tolerated volume. The impairment of resting and squeeze pressures, 
which are considered to be the expression of the internal and external anal sphincter 
function respectively  [39], has already been observed after rectal surgery [40,41]. Several 
factors may be implicated such as direct lesions due to stapling devices [9,42,43] or injury 
to the nervous pathway [44].  A significant difference can be observed between patients 
with medium or low rectal cancer in resting pressure, with the latter having worse resting 
pressure values both after CRT and after surgery. These data suggest that the localization 
of the rectal cancer might be predictive of the occurrence of anorectal dysfunction as 
measured by manometry and that this alteration mainly concerns the internal anal 
sphincter. Previous studies have suggested that a low level of anastomosis is a negative 
predictive index of anal continence after surgical treatment for rectal cancer however in 
these studies only surgical treatment and not neoadjuvant therapies were considered [45-
48].  
As expected we found a lower pressure threshold inducing urgency to defecate for the first 
time in 33% of the patients after surgery and in 6 of them it was the only manometric 
alteration. As previously reported, this sensory alteration most likely reflects the reduced 
capacity and distensibility of the rectum, [40]. It has been demonstrated that this alteration 
tends to recover after the sixth postoperative month [48], however in our study the 
manometric alteration persisted after 12 months of restored function.  
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A manometric alteration of the anorectal function does not necessarily correspond to 
symptoms, such as faecal incontinence. Indeed previous authors have demonstrated that 
faecal incontinence is determined by the simultaneous presence of different dysfunction of 
the anorectal structures [49].  
A limit of our study is that a validated incontinence score was not employed and the 
relation between anorectal dysfunction revealed by anorectal manometry and symptoms 
has not been analysed, further studies should clarify this aspect.  
In conclusion, the present study demonstrates that in a percentage of patients with rectal 
cancer an alteration of anal sphincter function as measured by anorectal manometry is 
already present before any treatment. CRT can be an aggravating factor, regardless of 
surgery, as it determines a decrease in anal sphincter resting pressure. Finally surgery 
represents a further detrimental factor significantly affecting both anal sphincter resting 
and squeeze pressure and reducing the sensory threshold, particularly in patients with low 
rectal cancer. The clinical implications of these results are that the maximal effort should 
be directed to develop therapeutical strategies to reduce anorectal dysfunction, and/or 
therapeutical options to manage the possible alterations.   
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Table 1. Clinical characteristics of patients’ population and relative manometric findings 
before any treatment, (T0), after chemoradiotherapy (T1) and after surgery (T2). Changes 
in manometric findings between evaluations at the different time-points are highlighted. 
 
ID 
S
e
x 
Age 
(ys) 
Site 
Cm 
from 
av 
Comor
bidity 
Previ
ous 
surg
ery 
Clinical 
Stage  
 
FI 
Score 
T0 
Manome
try T0 
FI 
Score 
T1 
Manome
try T1 
FI 
Score 
T2 
Manome
try T2 
Pathologic 
Stage 
Ana 
stom
osis 
1 m 64 L 5   T3N+ 
0 
N 
0 
N 
3 RP+SP+
UD 
T3N0 HS 
2 m 49 L 3 H CH T4N+ 0 N 0 N 4 RP+SP T0N0 HS 
3 f 60 L 4 H  T3N0 
0 
UD 
5 
SP+UD 
5 RP+SP+
UD 
T1N0 HS 
4 m 52 L 4   T3N+ 
0 
N 
0 
N 
4 RP+SP+
UD 
T2N0 HS 
5 m 70 L 6 H  T4N+ 
0 
N 
4 
N 
5 RP+SP+
UD 
T3N+ HS 
6 m 41 L 5   T2N+ 0 N 4 N 4 RP+UD T1N0 HS 
7 m 46 L 5   T3N+ 0 N 0 N 5 RP+UD T0N0 HS 
8 m 43 L 5   T3N+ 
0 
N 
0 
N 
0 RP+SP+
UD 
T3N0 HS 
9 f 72 L 4 HC  T3N+ 0 N 0 N     3 RP+SP T3N0 HS 
10 m 48 L 4   T3N+ 
0 
N 
0 
N 
0 RP+SP+
UD 
T3N0 HS 
11 m 75 L 4 H  T3N0 0 N 3 RP+UD 4 RP T2N0 HS 
12 f 79 L 4   T2N+ 0 N 0 UD 0 UD  T3N+ HS 
13 f 69 L 5   T3N+ 0 N 0 RP+UD 0 RP+UD T3N0 M 
14 m 80 L 6 D2+H  T3N+ 0 N 0 N     0 N T3N+ M 
15 f 67 M 8 D2 CH T3N+ 
0 
N 
0 
N 
0 RP+SP+
UD 
T3N+ M 
16 f 60 M 7 D1 
CH+
RC 
T3N+ 
2 
N 
3 
UD 
4 
UD T1N0 M 
17 f 74 M 7 H  T3N+ 0 UD 0 UD 0 UD T3N+ M 
18 f 70 M 11 H HY T4N+ 0 N 0 N 0 N T3N+ M 
19 m 65 M 8   T3N+ 0 UD 0 RP+UD 4 RP T2N0 M 
20 m 66 M 7   T3N+ 0 N 0 N 0 RP T0N0 M 
21 f 62 M 7 
D2+H
C 
 T3N+ 
0 
UD 
0 
N 
0 
N T2N+ M 
22 m 49 M 8   T3N+ 0 UD 0 UD 0 UD T3N+ M 
23 m 73 M 9 IHD 
CH+
PTC
A 
T3N+ 
0 
N 
0 
RP+UD 
0 
RP+UD T2N+ M 
24 m 74 M 7 H+IHD 
PTC
A 
T3N+ 
0 
N 
0 
N 
0 
N T0N0 M 
25 f 77 M 10 H  T3N+ 
2 
RP+SP 
4 RP+SP+
UD 
5 
SP+UD T0N0 M 
26 m 75 M 9   T3N+ 3 RP+UD 3 RP 3 RP T1N0 M 
27 m 47 M 8   T4N+ 0 UD 0 N 0 UD T2N+ M 
28  m 50 M 11 H  T3N+ 0 N 3 SP+UD 4 UD T2N0 M 
29 m 72 M 8 BPH  T3N+ 4 UD 5 UD 4 UD T3N+ M 
30 m 67 M 7 
H+BP
H 
 T3N0 
0 
N 
0 
N 
0 
N T0N0 M 
31 m 48 M 8   T2N+ 
0 
N 
0 
RP 
0 RP+SP+
UD 
T2N0 M 
32 m 71 M 9   T3N+ 
0 
SP 
4 RP+SP+
UD 
4 
N T3N+ M 
33 f 63 M 10 H  T4N+ 4 UD 4 UD 4 UD T3N0 M 
34 m 63 M 10   T3N+ 0 N 0 N 0 SP+UD T1N0 M 
35 m 74 M 9 D2+H  T3N+ 
0 
N 
0 
RP 
3 RP+SP+
UD 
T0N+ M 
36 f 61 M 7 H HY T3N+ 0 N 0 N 0 UD T3N+ M 
37 m 47 M 8   T3N0 0 N 0 UD 0 UD T2N0 M 
38 f 55 M 8   T3N+ 0 UD 0 UD 0 UD T0N0 M 
39 m 58 M 9  HE T2N+ 
0 
N 
0 
N 
0 RP+SP+
UD 
T2N0 M 
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L: low rectal cancer  
M: medium rectal cancer 
H: hypertension 
HC: hypercholesterolemia 
D2: type II Diabetes 
D 1: type I Diabetes 
IHD: ischemic heart disease 
BPH: benign prostatic hypertrophy 
CH: cholecistectomy 
RC: right colectomy 
HI: hysterectomy 
PTCA: percutaneous transluminal coronary angioplasty 
HE: hemorrhoidectomy 
T0: before neoadjuvant therapy 
T1: after neoadjuvant therapy and before surgery 
T2: 12 months after stoma closure 
FI Score: Pescatori incontinence score 
RP: resting pressure below normal values 
SP: squeeze pressure below normal values 
UD: volume threshold for urgency below normal values 
HS: hand sewn 
M: mechanical 
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Table 2. Demographic, clinical and manometric parameters before any treatment in the 
whole patients’ population and in the subgroups of patients with medium and low rectal 
cancer. Mean value and standard deviation for each parameter. 
 
 
 Whole 
Patients 
Group 
Medium 
Rectal 
Cancer 
Low 
Rectal 
Cancer 
 
P-value 
Patient N° 39 25 14 NS 
Females 13 9 4 NS 
Males 26 16 10 NS 
Age 62±11 63±10 62±10 NS 
Comorbidities 20 18 7 NS 
Previous 
pelvic surgery 
3 3 0 NS 
cT2N+ 4 2 2 NS 
cT3N0 4 2 2 NS 
cT3N+ 26 18 8 NS 
cT4N+ 5 3 2 NS 
FI score 0.38 ± 1.06 0.6 ± 1.29 0 ± 0 NS 
Resting 76±23 73±20 83±21 NS 
Squeeze 239±99 234±90 249±89 NS 
F 23±11 20±10 27±12 NS 
D 42±22 40±21 48±22 NS 
U 103±47 89±30 132±32 *0.01 
RAIR 22±8 24±7 20±8 NS 
 
 
 
 
 
Resting = resting pressure (mm Hg) 
C= clinical stage at diagnosis 
Squeeze = maximum squeeze pressure (mm Hg) 
F = volume threshold inducing first sensation (ml)  
D = volume threshold inducing desire to defecate (ml) 
U = volume threshold inducing urgency to defecate (ml) 
RAIR = recto-anal inhibitory reflex 
* P= 0.01 Low vs Medium Rectal Cancer 
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Table 3. Manometric parameters in the whole patients’ population before any treatment, 
after CRT and after surgery. Mean value and standard deviation for each parameter. 
 
 
T0 T1 P-value T2 P-value 
Resting 
76±23 63±22 * 0.007 38±18 †‡<0.001 
Squeeze 
239±99 211±88 NS 142±60 †‡<0.001 
F 
23±11 20±3 NS 20±1 NS 
D 
42±22 39±21 NS 36±40 NS 
U 
103±47 93±43 NS 47±37 †‡<0.001 
RAIR 
22±8 22±8 NS 20±1 NS 
 
T0 = before neoadjuvant therapy 
T1 = after neoadjuvant therapy and before surgery 
T2 = 12 months after stoma closure 
Resting = resting pressure 
Squeeze = maximum squeezing pressure  
F = pressure threshold inducing first sensation   
D = pressure threshold inducing desire to defecate   
U = pressure threshold inducing urgency to defecate  
RAIR = recto-anal inhibitory reflex 
*  P= 0.007 evaluation after chemoradiotherapy vs before any treatments 
†  P<0.001 evaluation after surgery vs after radiotherapy 
‡  P<0.001 evaluation after surgery vs before any treatments 
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Table 4. Manometric parameters in the two subgroups of patients with medium and low 
rectal cancer before any treatment, after RCT and after surgery. Mean value and standard 
deviation for each parameter. 
 
Medium 
rectal 
cancer 
T0 T1 T2 P-value 
Low 
rectal 
cancer 
T0 T1 T2 P-value 
Resting 73±20 61±22 § 50±15 § 0.001 Resting 83±23 66±22 *† 27±18 
* <0.007 
† <0.001 
Squeeze 234±90 
198±8
8 
166±58 NS Squeeze 249±99 226±88 *† 120±60 
* <0.007 
† <0.001 
F 20±11 20±3 20±1 NS F 27±11 21±3 20±1 NS 
D 40±22 41±21 30±24 NS D 48±22 37±21 43±40 NS 
U ‡ 89±47 91±43 47±33 ‡ 0.01 U 132±47 96±43 * 48±37 * <0.007 
RAIR 24±8 22±8 30±16 NS RAIR 20±8 21±8 20±1 NS 
 
 
T0 = evaluation before neoadjuvant therapy 
T1 = evaluation after neoadjuvant therapy and before surgery 
T2 = evaluation 12 months after stoma closure 
Resting = resting pressure 
Squeeze = maximum squeezing pressure  
F = pressure threshold inducing first sensation   
D = pressure threshold inducing desire to defecate   
U = pressure threshold inducing urgency to defecate 
RAIR = recto-anal inhibitory reflex 
 
 *P< 0.007 evaluation after surgery vs after chemoradiotherapy in the subgroup of patients 
with low rectal cancer. 
 † P< 0.001 evaluation after surgery vs before any treatment in the subgroups of patients 
with low rectal cancer. 
 ‡P= 0.01 evaluation before any treatments in the subgroup of patients with medium vs low 
rectal cancer. 
 §P=0.001 evaluation after surgery in the subgroup of patients with medium vs low rectal 
cancer. 
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Age > 
60 years 
T0 T1 T2 P-value 
Age ≤ 
60 years 
T0 T1 T2 P-value 
Resting 
75.6± 
23.8 
59.4± 
21.1 
40±18.1 
*0.02 
†0.008 
‡<0.001 
Resting 
77.8± 
22.8 
71.4±23.4 36.1±19.9 
†<0.001 
‡<0.001 
Squeeze 
223.4±
92.2 
199±81 153±67.2 
 
‡0.02 
Squeeze 
226.5± 
109.6 
232.1±98 130.1±51.5 
†0.004 
‡0.001 
F 
21 ± 
4.5 
20±0 20±0 NS F 
26.7± 
17.75 
22.85±7.3 20±14.9 NS 
D 
38.9± 
21.6 
40.9± 
26.4 
48.6±54 NS D 
49.1± 
24.3 
36.9±11.1 23.3±8.2 
†0.01 
‡0.02 
U 
98.9± 
38.6 
90.9± 
41.7 
56.9± 
45.3 
†0.03 
‡0.008 
U 110±60 98.5±47.2 36±20.6 
†<0.001 
‡0.001 
RAIR 
24.2± 
10.7 
22.7± 
9.35 
20±0 NS RAIR 20±0 21.5±5.5 20±0 NS 
 
 
D = pressure threshold inducing desire to defecate   
F = pressure threshold inducing first sensation   
RAIR = recto-anal inhibitory reflex 
Resting = resting pressure 
Squeeze = maximum squeezing pressure 
T0 = evaluation before neoadjuvant therapy 
T1 = evaluation after neoadjuvant therapy and before surgery 
T2 = evaluation 12 months after stoma closure  
U = pressure threshold inducing urgency to defecate 
* P < 0.05 T0 vs T1 
† P < 0.05 T1 vs T2 
‡ P < 0.05 T0 vs T2 
T0 > 60 vs T0 ≤ 60 NS 
T1 > 60 vs T1 ≤ 60 NS 
T2 > 60 vs T2 ≤ 60 NS 
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Male T0 T1 T2 P-value Female T0 T1 T2 P-value 
Resting 
79.2± 
20.5 
68.1± 
21.9 
37.6± 
19.7 
†<0.001 
‡<0.001 
Resting 
70.3± 
28.2 
55.3±22 
39.6± 
16.9 
‡0.02 
Squeeze 
269± 
102.5 
245.4± 
81.7 
158.1± 
62.8 
†<0.001 
‡<0.001 
Squeeze 
174.9± 
53.6 
141.1± 
52.6 
104.8± 
33.4 
‡0.008 
§ 0.01 
^<0.001 
°0.04 
F 
24.5± 
13.7 
20.8±4 26.6±13 
†<0.001 
 
F 20±0 20±0 20±0 NS 
D 
42.7± 
24.1 
35.6± 
13.4 
30±21.4 NS D 
42.5± 
19.8 
47.3± 
32.6 
48± 
62.6 
NS 
U 
113.6± 
47.6 
102.6± 
43.2 
45±32.2 
†<0.001 
‡<0.001 
U 
77.8± 
38 
76.7± 
39.8 
54.3± 49.9 NS 
RAIR 21.9±6 22.5±9 20±0 NS RAIR 25±14.1 21.8±6 20±0 NS 
 
 
D = pressure threshold inducing desire to defecate   
F = pressure threshold inducing first sensation   
RAIR = recto-anal inhibitory reflex 
Resting = resting pressure 
Squeeze = maximum squeezing pressure 
T0 = evaluation before neoadjuvant therapy 
T1 = evaluation after neoadjuvant therapy and before surgery 
T2 = evaluation 12 months after stoma closure  
U = pressure threshold inducing urgency to defecate 
† P < 0.05 T1 vs T2 
‡ P < 0.05 T0 vs T2 
§ P < 0.05 T0 Male vs T0 Female  
^ P < 0.05 T1 Male vs T1 Female  
° P < 0.05 T2 Male vs T2 Female  
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Hand-sewn 
anastomosis 
T2 
Mechanical 
anastomosis 
T2 P-value 
Resting 26.8±14.6 Resting 49.6±15.2 °0.001 
Squeeze 119.6±54.7 Squeeze 165.6±58.9 NS 
F 20±0 F 20±0 NS 
D 42.8±52.2 D 30±24.5 NS 
U 48.3±42.2 U 47.3±33.8 NS 
RAIR 20±0 RAIR 20±0 NS 
 
 
D = pressure threshold inducing desire to defecate   
F = pressure threshold inducing first sensation   
RAIR = recto-anal inhibitory reflex 
Resting = resting pressure 
Squeeze = maximum squeezing pressure 
T2 = evaluation 12 months after stoma closure  
U = pressure threshold inducing urgency to defecate 
° P < 0.05 T2 Hand-sewn anastomosis vs T2 Mechanical anastomosis  
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Low 
rectal 
cancer < 
5 cm 
from 
anal 
verge 
T0 T1 T2 P-value 
Low 
rectal 
cancer 
≥ 5 cm 
from 
anal 
verge 
T0 T1 T2 P-value 
Resting 
79± 
25.5 
 
68± 
18.8 
 
22.8± 
11.9 
 
†<0.001 
‡0.001 
Resting 
89.8± 
22.5 
 
74.4± 
30.3 
 
27.5± 
18.1 
 
†0.02 
‡0.002 
Squeeze 
228,5± 
40.8 
 
217.6± 
99.9 
115.7± 
65.5 
 
*0.01 Squeeze 
277± 
122.5 
 
256.8± 
86.1 
 
138± 
52.7 
 
†0.03 
 
F 
25± 
10 
 
22.8± 
7.5 
 
20±0 
 
NS F 
32± 
26.8 
 
20±0 
 
20±0 
 
NS 
D 
55± 
34.1 
 
45.7± 
35.9 
 
46.7± 
56.1 
 
NS D 
48± 
22.8 
 
31.4± 
15.7 
 
20±0 
 
NS 
U 
115± 
59.7 
 
111.4± 
68.2 
 
73.3± 
48.4 
 
NS U 
156± 
29.4 
 
91.4± 
27.9 
 
20±0 
 
*0.004 
‡<0.001 
†<0.001 
RAIR 
20±0 
 
22.8± 
7.5 
 
20±0 NS RAIR 20±0 20±0 20±0 NS 
 
 
D = pressure threshold inducing desire to defecate   
F = pressure threshold inducing first sensation   
RAIR = recto-anal inhibitory reflex 
Resting = resting pressure 
Squeeze = maximum squeezing pressure 
T0 = evaluation before neoadjuvant therapy 
T1 = evaluation after neoadjuvant therapy and before surgery 
T2 = evaluation 12 months after stoma closure  
U = pressure threshold inducing urgency to defecate 
† P < 0.05 T1 vs T2 
‡ P < 0.05 T0 vs T2 
* P < o.o5 T0 vs T1 
§ P < 0.05 T0 Low rectal cancer < 5 cm from anal verge vs T0 Low rectal cancer ≥ 5 cm 
from anal verge NS 
^ P < 0.05 T1 Low rectal cancer < 5 cm from anal verge vs T1 T0 Low rectal cancer ≥ 5 cm 
from anal verge NS 
° P < 0.05 T2 Low rectal cancer < 5 cm from anal verge vs T2 Low rectal cancer ≥ 5 cm 
from anal verge NS 
 
 
 
 
 23 
 
Medium 
rectal 
cancer < 
9 cm 
from 
anal 
verge  
T0 T1 T2 P-value 
Medium 
rectal 
cancer ≥ 
9 cm 
from 
anal 
verge 
T0 T1 T2 P-value 
Resting 
77.9± 
18.9 
64.7± 
18.6 
49.1± 
14.6 
 
 
‡0.001 
Resting 
66.8± 
26.6 
 
49.9± 
21.4 
 
46.2± 
17.8 
 
NS 
Squeeze 
266.5± 
109.5 
 
213.7± 
73.9 
 
177± 
67.8 
 
NS Squeeze 
190.3± 
79.8 
 
162.6± 
95.7 
 
126.7± 
35.9 
 
NS 
F 
20±0 
 
20±0 
 
20±0 
 
NS F 
22± 
6.3 
 
20±0 
 
20±0 
 
NS 
D 
32.7± 
13.5 
 
42.9± 
18.9 
 
35±30 
 
NS D 
46± 
25 
 
33.3± 
10.3 
 
20±0 
 
NS 
U 
80± 
41.8 
 
98.6± 
39.6 
 
51.4± 
41.4 
†0.02 U 
100± 
36.5 
 
68.6± 
25.4 
 
36.7± 
15 
 
‡0.001 
†0.02 
RAIR 
20±0 
 
24.3± 
11.6 
 
20±0 
 
NS RAIR 
30± 
15.1 
 
20±0 
 
20±0 
 
NS 
§0.02 
 
D = pressure threshold inducing desire to defecate   
F = pressure threshold inducing first sensation   
RAIR = recto-anal inhibitory reflex 
Resting = resting pressure 
Squeeze = maximum squeezing pressure 
T0 = evaluation before neoadjuvant therapy 
T1 = evaluation after neoadjuvant therapy and before surgery 
T2 = evaluation 12 months after stoma closure  
U = pressure threshold inducing urgency to defecate 
† P < 0.05 T1 vs T2 
‡ P < 0.05 T0 vs T2 
* P < o.o5 T0 vs T1 
§ P < 0.05 T0 Medium rectal cancer < 9 cm from anal verge vs T0 Medium rectal cancer ≥ 
9 cm from anal verge  
^ P < 0.05 T1 Medium rectal cancer < 9 cm from anal verge vs T1 T0 Medium rectal 
cancer ≥ 9 cm from anal verge NS 
° P < 0.05 T2 Medium rectal cancer < 9 cm from anal verge vs T2 Medium rectal cancer ≥ 
9 cm from anal verge NS 
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Fig. 1. Flow chart of included patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 pts elegible      
                   42 pts enrolled 
48 pts with advanced rectal cancer 
(April 2011-2012)  
2 pts refused to participate 
 
Pts excluded 
1 pt: short course neoadjuvant 
therapy 
3 pts: neoadjuvant treatment not 
at our Institution 
 
 39 pts included 
Pts excluded 
1 pt: intersphincteric resection  
2 pts: abdominoperineal excision 
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